Table 2 Baseline characteristics of the included patients

From: D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis

 

Total cohort (n = 114), n (%)

No VTE recurrence (n = 104), n (%)

VTE recurrence (n = 10), n (%)

Age, mean ± SD (years)

61.7 ± 13.7

61.8 ± 13.7

59.9 ± 14.3

Male, n (%)

58 (51.3)

51 (50)

7 (70)

Haematological cancer, n (%)

16 (14.3)

14 (13.9)

2 (20)

Solid tumour, n (%)

  Breast

20 (17.9)

18 (17.8)

2 (20)

  Colorectal

20 (17.9)

20 (19.8)

0 (0)

  Lung

12 (10.7)

9 (8.9)

3 (30)

  Prostate

9 (8)

9 (7.9)

1 (10)

  Bladder

6 (5.4)

6 (5.9)

0 (0)

  Kidney

3 (2.7)

2 (2)

1 (10)

  Pancreas

2 (1.8)

1 (1)

1 (10)

  Brain

2 (1.8)

2 (2)

0 (0)

  Others

22 (19.6)

21

0

Metastasis

45 (39.8)

39 (37.9)

6 (60)

ECOG performance status, n (%)

  0

56 (49.1)

52 (50.5)

4 (40)

  1

51 (44.7)

46 (44.5)

5 (50)

  2

3 (2.6)

3 (2.9)

0 (0)

  3

1 (0.9)

1 (1)

0 (0)

  4

3 (2.6)

2 (1.9)

1 (10)

VTE presentation, n (%)

  DVT

61 (53.5)

55 (53.4)

6 (60)

  PE

33 (28.9)

33 (32)

0 (0)

  DVT+PE

13 (11.4)

9 (8.6)

4 (40)

  Atypical VTE location

7 (6.1)

7 (6.8)

0 (0)

Incidental VTE, n (%)

33 (29)

33 (32)

0 (0)

VTE recurrence

10 (8.8)

—

—

Death

10 (8.8)

6 (5.9)

2 (20)

  1. VTE venous thromboembolism, SD standard deviation, ECOG Eastern Cooperative Oncology Group, DVT deep vein thrombosis, PE pulmonary embolism
Back to article page